{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Stage1%3A+Placebo",
    "query": {
      "intervention": "Stage1: Placebo"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 98,
    "total_pages": 10,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Stage1%3A+Placebo&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-16T12:47:06.704Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07349771",
      "title": "Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematopoietic and Lymphatic System Neoplasm"
      ],
      "interventions": [
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Axatilimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Placebo Administration",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Skin Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "X-Ray Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2026-06-01",
      "completion_date": "2033-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-09-16T12:47:06.704Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07349771"
    },
    {
      "nct_id": "NCT02277106",
      "title": "Evaluate SAGE-547 in Participants With Essential Tremor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Essential Tremor"
      ],
      "interventions": [
        {
          "name": "SAGE-547",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sage Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "35 Years to 75 Years"
      },
      "enrollment_count": 25,
      "start_date": "2014-09-23",
      "completion_date": "2015-08-14",
      "has_results": true,
      "last_update_posted_date": "2022-06-29",
      "last_synced_at": "2026-09-16T12:47:06.704Z",
      "location_count": 2,
      "location_summary": "Bingham Farms, Michigan • Raleigh, North Carolina",
      "locations": [
        {
          "city": "Bingham Farms",
          "state": "Michigan"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02277106"
    },
    {
      "nct_id": "NCT06236438",
      "title": "Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Livmoniplimab",
          "type": "DRUG"
        },
        {
          "name": "Budigalimab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 840,
      "start_date": "2024-04-10",
      "completion_date": "2031-10",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-09-16T12:47:06.704Z",
      "location_count": 19,
      "location_summary": "La Jolla, California • Pembroke Pines, Florida • Winter Haven, Florida + 16 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "Winter Haven",
          "state": "Florida"
        },
        {
          "city": "Athens",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06236438"
    },
    {
      "nct_id": "NCT05066997",
      "title": "A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Dexamethasone ophthalmic suspension (OCS-01)",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oculis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 552,
      "start_date": "2021-10-19",
      "completion_date": "2026-04-10",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-09-16T12:47:06.704Z",
      "location_count": 40,
      "location_summary": "Phoenix, Arizona • Springdale, Arkansas • Beverly Hills, California + 35 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05066997"
    },
    {
      "nct_id": "NCT00770861",
      "title": "A Study on the Efficacy and Safety of Nebivolol Monotherapy in Hispanic Hypertensive Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Nebivolol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 277,
      "start_date": "2008-09",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2011-01-26",
      "last_synced_at": "2026-09-16T12:47:06.704Z",
      "location_count": 29,
      "location_summary": "Buena Park, California • Chino, California • Long Beach, California + 19 more",
      "locations": [
        {
          "city": "Buena Park",
          "state": "California"
        },
        {
          "city": "Chino",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "National City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00770861"
    },
    {
      "nct_id": "NCT01658436",
      "title": "BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Neuroendocrine Tumors (pNET)"
      ],
      "interventions": [
        {
          "name": "BEZ235 (Stage 1)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2012-11",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2016-05-02",
      "last_synced_at": "2026-09-16T12:47:06.704Z",
      "location_count": 4,
      "location_summary": "Indianapolis, Indiana • Boston, Massachusetts • The Bronx, New York + 1 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01658436"
    },
    {
      "nct_id": "NCT00307125",
      "title": "Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Transplant",
        "Kidney Transplant Recipient",
        "Graft Function/Survival",
        "de Novo HLA Antibodies Development"
      ],
      "interventions": [
        {
          "name": "Rituximab plus immunosuppression",
          "type": "DRUG"
        },
        {
          "name": "Placebo plus immunosuppression",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "5 Years to 70 Years"
      },
      "enrollment_count": 757,
      "start_date": "2006-03",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2015-03-23",
      "last_synced_at": "2026-09-16T12:47:06.704Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Gainesville, Florida + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00307125"
    },
    {
      "nct_id": "NCT01520116",
      "title": "Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Primary Open Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Stage 1 - ATS907 - Dose 1",
          "type": "DRUG"
        },
        {
          "name": "Stage 1 - ATS907 - Dose 2",
          "type": "DRUG"
        },
        {
          "name": "Stage 1 - ATS907 - Dose 3",
          "type": "DRUG"
        },
        {
          "name": "Stage 1 - ATS907 - Dose 4",
          "type": "DRUG"
        },
        {
          "name": "Stage 1 - Vehicle",
          "type": "DRUG"
        },
        {
          "name": "Stage 2 - ATS907 - Dose A - to be selected based on Stage 1",
          "type": "DRUG"
        },
        {
          "name": "Stage 2 - ATS907 - Dose B - to be selected based on Stage 1",
          "type": "DRUG"
        },
        {
          "name": "Timoptic",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Altheos, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2012-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2012-11-01",
      "last_synced_at": "2026-09-16T12:47:06.704Z",
      "location_count": 5,
      "location_summary": "Artesia, California • Glendale, California • Saint Joseph, Michigan + 2 more",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Saint Joseph",
          "state": "Michigan"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01520116"
    },
    {
      "nct_id": "NCT03523728",
      "title": "A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Polycystic Kidney, Autosomal Dominant"
      ],
      "interventions": [
        {
          "name": "Venglustat",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 478,
      "start_date": "2018-10-04",
      "completion_date": "2021-08-03",
      "has_results": true,
      "last_update_posted_date": "2023-02-03",
      "last_synced_at": "2026-09-16T12:47:06.704Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03523728"
    },
    {
      "nct_id": "NCT01904721",
      "title": "A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alopecia",
        "Alopecia, Androgenetic",
        "Baldness"
      ],
      "interventions": [
        {
          "name": "Bimatoprost Solution 1",
          "type": "DRUG"
        },
        {
          "name": "Bimatoprost Solution 2",
          "type": "DRUG"
        },
        {
          "name": "Bimatoprost Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "MALE",
        "summary": "18 Years to 49 Years · Male only"
      },
      "enrollment_count": 244,
      "start_date": "2013-08",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2016-03-22",
      "last_synced_at": "2026-09-16T12:47:06.704Z",
      "location_count": 1,
      "location_summary": "Fridley, Minnesota",
      "locations": [
        {
          "city": "Fridley",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01904721"
    }
  ]
}